A critical barrier to the development of a human immunodeficiency virus (HIV) cure is the lack of an appropriate and scalable preclinical animal model that enables robust evaluation of candidate eradication approaches prior to testing in humans. Humanized mouse models typically involve engraftment of human fetal tissue and currently face ethical and political challenges. We established a fetal tissue-free humanized model of latent HIV infection, by transplanting "J-Lat" cells, Jurkat cells harboring a latent HIV provirus encoding an enhanced green fluorescent protein (GFP) reporter, into irradiated adult NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. J-Lat cells exhibited successful engraftment in several tissue sites, including spleen, bone barrow, peripheral blood, and lung, mirroring the diverse tissue tropism of HIV in the human host. Administration of tumor necrosis factor (TNF)-α, an established HIV latency reversal agent, significantly induced GFP expression in engrafted cells across tissues (as measured by flow cytometry at necropsy), reflecting viral reactivation. These data suggest that the "μ-Lat" model enables efficient determination of how effectively viral eradication agents, including latency reversal agents, penetrate and function in diverse anatomical sites harboring HIV in vivo. 3
Introduction
The advent of antiretroviral therapy (ART) has dramatically reduced morbidity and mortality for human immunodeficiency virus (HIV)-infected individuals with access to healthcare in resourcerich countries. However, despite years of potent therapy, eradication of infection is not achieved due to the persistence of HIV latently-infected cells during treatment (1) . Accumulating evidence suggest that "non-AIDS" cardiovascular, renal and hepatic diseases are amplified by HIV infection, and the immune system may exhibit premature senescence even among patients with complete viral suppression (2) . Moreover, although enormous progress has been made to provide ART in resource limited settings, there are huge economic, political and operational challenges to reach the goal of universal access to lifelong treatment. These realities have created a pronounced interest in developing HIV cure strategies.
Elimination of the latent HIV reservoir is critical to achieving HIV eradication in vivo. A number of approaches are currently under investigation, including therapeutic vaccination, immunomodulatory approaches, ART intensification, therapeutic HIV latency reversal (the "shock and kill" strategy), as well as a number of gene therapy approaches (3, 4) . In all scenarios, it will be critical to have proper diagnostic tools and models in place to comprehensively evaluate performance and safety prior to deployment in a clinical setting. A critical barrier to the development of an HIV cure is the lack of an appropriate, accessible, and scalable preclinical animal model that enables robust evaluation of candidate eradication approaches prior to testing in humans (5) . As a result, many promising curative approaches never graduate past the petri dish stage. Infection of nonhuman primates (NHP) with simian immunodeficiency virus (SIV) is an option and has been utilized extensively to study HIV/AIDS pathogenesis (6, 7) . Recent advancements have been made in optimizing ART regimens to achieve durable virus suppression and thus enable evaluation of HIV cure strategies in the SIV-NHP model (8) (9) (10) . However, biological limitations remain since this model uses SIV and might not recapitulate human host-HIV interactions and HIV latency mechanisms (11) (12) (13) (14) (15) . In addition, NHP experiments involve complex ethical considerations, and the high costs and labor requirements only allow small numbers of animals to be utilized in any given trial, limiting statistical power and generalizability (11) .
Mouse models represent another alternative with lower costs, more convenient husbandry requirements, as well as greater scalability. In the context of HIV studies, a wide range of small animal models have been developed comprising knockout mouse models (16) (17) (18) , transgenic mouse (19) (20) (21) (22) (23) and humanized mouse models (6, (24) (25) (26) (27) (28) (29) . Humanized mice are established by xenotransplantation of human cells or tissues in immunodeficient mouse strains. Most strains used in HIV research are derivatives of severe combined immunodeficient (SCID) mice, which harbor mutations in the gene coding for a DNA-dependent protein kinase catalytic subunit (Prkdc). These mice are "humanized" using two approaches: 1) human cells are injected with or without prior irradiation of mice or 2) portions of tissue are surgically implanted. Different cells have been used for injection comprising human peripheral blood mononuclear cells (PBMCs), as in the hu-PBL-SCID mouse model (30) , obtained from healthy (31) or HIV-infected ART suppressed individuals (32) , or human hematopoietic stem cells (HSCs), as in the hu-HSC mouse model (33) , or the more recently developed T-cell-only(34) and myeloid-only(35) mouse models (ToM and MoM). Implantation of fetal thymus and liver tissue fragments are used for the SCID-hu thy/liv (36, 37) and bone marrow/liver/thymus (BLT)(38,39) mouse models. Although all these 6 model systems have contributed to our understanding of HIV pathogenesis and persistence, key limitations remain that need to be addressed in order to fully exploit the potential of these small animal models in HIV cure research. Hu-PBL-SCID mice struggle with the development of graft versus host disease (GVHD) which renders this model inapplicable for long-term studies involving HIV persistence. The generation of SCID-hu thy/liv mice and BLT mice is limited due to the need for surgical implantation and a limited supply of tissue. Moreover, these models as well as hu-HSC, ToM and MoM mice rely on the engraftment of cells or tissues typically derived from human fetal specimens, which in light of recent changes in federal policies, now face significant challenges, as ethical, legal, and political considerations surrounding the use of fetal tissue in scientific research have made it increasingly difficult to obtain such material (40, 41) . A major limitation shared by all these models remains the low frequency of HIV-latently infected cells, which impacts the applicability of these models as robust preclinical in vivo test bases for HIV cure strategies.
In the present study, we therefore pursued a new approach and transplanted J-Lat 11.1 cells (J-Lat cells), Jurkat cells harboring a latent HIV provirus encoding an enhanced green fluorescent protein (GFP) reporter, into irradiated adult NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. By applying an established and widely-utilized HIV latency reporter cell line (42) (43) (44) , we circumvent the need for fetal or any other donor-derived tissue, and achieve high frequencies of HIV latentlyinfected cells in vivo on a short experimental time scale. In addition, the presence of the GFP reporter cassette in the integrated viral genome provides for quick and convenient assessment of viral reactivation using flow cytometry or microscopy. Our data show robust engraftment of J-Lat cells in several tissues three weeks after injection as well as significant reactivation of these 7 latently infected cells in vivo upon intravenous administration of the established latency reversal agent (LRA) tumor necrosis factor (TNF)-α. We hereby show that our "µ-Lat" humanized mouse model enables rapid and efficient testing of HIV latency reversal approaches in vivo. Although not intended to serve as a pathophysiology model, we present this approach as a scalable, accessible, and cost-effective preclinical testbed to evaluate the safety, tolerability, and performance of HIV cure strategies in distinct anatomical niches.
Results
The human cell surface proteins CD147 and CD29 enable clear and reliable discrimination of J-Lat cells from mouse cells. Our model involves transplantation of J-Lat cells (immortalized human T cells harboring latent HIV provirus with a GFP reporter reflecting viral transcriptional activity) into irradiated adult NSG mice (42) . We therefore searched for cell surface markers that reliably identify engrafted J-Lat cells in a background of mouse cells, exhibiting three key features: 1) universal expression across J-Lat cells, 2) high per-cell expression on J-Lat cells, and 3) absence of expression on the surface of mouse cells.
Our candidate panel included seven cell surface proteins commonly known to be expressed in human CD4+ T cells: CD45, CD4, TCR α/β, CD27, CD147, CD29, and HLA-ABC. Among these, four cell surface markers were found to be expressed universally among the J-Lat population: CD45, CD147, CD29 and HLA-ABC (Fig. 1A) . The mean fluorescence intensity (MFI) of these four proteins was measured, reflecting the relative abundance of each protein on the cell surface. CD147 exhibited the highest MFI, followed by CD29 ( Fig. 1B ). We next tested if the CD29 and CD147 antibodies (used in combination to achieve maximum signal to noise ratio in the APC-channel) showed detectable binding to mouse cells obtained from bone marrow (BM), spleen, lung, and peripheral blood (PB). In preparation for subsequent engraftment experiments, PB harvest was performed in three different ways: by retro-orbital bleed (r. (mean = 6.1%), and spleen (mean = 0.6%) along with a GFP background signal not exceeding 5% in these tissues ( Fig. 2B ). Regarding PB harvest, highest engraftment levels of J-Lat cells were found after heart bleed with an average of 21.4%, followed by r.-o. bleed with a mean of 15%, and GFP background signals less than 2%, while on average 0.5% engrafted J-Lats were detected after tail vein bleed without exhibiting GFP background signal (Fig. 2C ). Due to considerable engraftment levels and practicality of collection, we decided to harvest PB in subsequent experiments via r.-o. bleeding. We thus established a suitable engraftment and sample collection protocol to drive the model (Fig. 3 ).
TNF-α treatment leads to GFP expression in tissue engrafted J-Lat cells reflecting reactivation
of latent provirus in vivo. Following refinement of the protocol for J-Lat engraftment in NSG mice, we sought to determine if HIV LRA administration would result in viral reactivation in vivo.
Viral reactivation was measured as %GFP expressing cells within engrafted cells following LRA treatment (Fig. 3) .
The proviruses within the J-Lat family of clones were selected to be responsive to TNF-α stimulation, resulting in viral LTR-driven GFP expression (42) . extensively within a single infected individual (63) (64) (65) . Therefore, it needs to be considered that any applied model system or cells from any given individual will influence predicted responses for the general population with a certain bias just as a cell line-based system (26) .
Our work described here represents a proof of concept, demonstrating that the engraftment of a cell line-based model of HIV latency may constitute a useful testbed for HIV cure strategies.
This general approach is highly versatile and should allow for a broad range of infected cell types to be examined in vivo. For example, HIV latency in the myeloid compartment is likely critical to viral persistence(35, [66] [67] [68] [69] , and multiple reports suggest this compartment may respond quite differently to curative approaches, as compared to lymphoid reservoirs (70, 71) . It may be fruitful to inject the U1 HIV chronically-infected promonocytic cell line (72) into NSG mice to examine LRA responses in myeloid cells. Building further on the myeloid theme, the central nervous system (CNS) compartment is an important viral sanctuary site in the setting of ART (71, (73) (74) (75) (76) , and HIV eradication approaches will almost certainly face unique challenges in this niche (76, 77) . As direct injection of human cells into the murine CNS has been used successfully as an engraftment approach(78-82), site-specific injection of the recently developed HC69.5 HIV latently-infected microglial cell line (83, 84) into the brains of NSG mice may provide a convenient platform to gauge CNS-focused cure strategies.
Beyond preclinical investigation of LRAs, the µ-Lat framework may provide a convenient model system to evaluate gene therapy-based HIV eradication approaches. Gene therapy approaches targeting HIV infection generally fall into two categories: 1) Gene editing can be used to target or "excise" the HIV provirus directly in infected cells as an eradication approach (85, 86) or 2) Editing can be used to modulate host cells to render them refractory to HIV infection and/or potentiate 15 antiviral immune responses (87) . In the former case, in vivo delivery of the gene therapy modality will likely be necessary to pervasively attack the HIV reservoir within a broad range of tissue sites in infected individuals. The µ-Lat model is well-suited to investigate gene delivery in this context, Adult female and male mice (≥8 weeks old) were included in this study and were maintained at the Vitalant Research Institute (VRI). Breeding pairs of NSG mice were obtained from Jackson Laboratories (Bar Harbor, ME), and were bred and maintained at VRI in a vivarium free from >40 murine pathogens as determined through biannual nucleic acid testing (Mouse Surveillance Plus PRIA; Charles River) of sentinel mice exposed to mixed bedding. Mice were maintained in sterile, disposable microisolator cages (Innovive, Inc.), which were changed every 14 days. 
Engraftment analysis of J-Lat cells in mice by flow cytometry:
Transplanted mice were sacrificed by cervical dislocation 3 weeks post-injection. BM, spleen, lung tissues and PB were harvested.
Single cell suspensions from the BM, spleen, and PB were prepared as described previously by Beyer et al. (89) . Lung specimens were processed as follows: after harvest, lung samples were stored in PBS on ice. Lung specimens were washed twice with PBS and then cut into 3-4 mm 2 pieces in a petri dish in 1 ml digestion solution consisting of 1 mg/ml DE Collagenase (Cat. #011- 
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